Salus Therapeutics develops single stranded RNAi therapeutics.

History:

Salus Therapeutics was acquired by Genta in 2003.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Other US

Research Focus:
RNAi Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: